Cross-Site Reliability of Human Induced Pluripotent stem cell-derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study

Ando, 2017, A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes, J. Pharmacol. Toxicol. Methods, 84, 111, 10.1016/j.vascn.2016.12.003

Asai, 2010, Combination of functional cardiomyocytes derived from human stem cells and a highly-efficient microelectrode array system: An ideal hybrid model assay for drug development, Curr. Stem Cell Res. Ther, 5, 227, 10.2174/157488810791824502

2015, Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes, J. Pharmacol. Toxicol. Methods, 75, 17, 10.1016/j.vascn.2015.04.002

Bland, 1986, Statistical methods for assessing agreement between two methods of clinical measurement, Lancet (London, England), 327, 307, 10.1016/S0140-6736(86)90837-8

Blinova, 2017, Comprehensive translational assessment of human-induced pluripotent stem cell derived cardiomyocytes for evaluating drug-induced arrhythmias, Toxicol. Sci, 155, 234, 10.1093/toxsci/kfw200

Braam, 2013, Repolarization reserve determines drug responses in human pluripotent stem cell derived cardiomyocytes, Stem Cell Res, 10, 48, 10.1016/j.scr.2012.08.007

Braam, 2010, Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes, Stem Cell Res, 4, 107, 10.1016/j.scr.2009.11.004

Clements, 2014, High-throughput multi-parameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays, Toxicol. Sci, 140, 445, 10.1093/toxsci/kfu084

Crumb, 2016, An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel, J. Pharmacol. Toxicol. Methods, 81, 251, 10.1016/j.vascn.2016.03.009

Fridericia, 2003, The Duration of Systole in an Electrocardiogram in Normal Humans and in Patients with Heart Disease, Acta Med. Scand, 8, 343

Guo, 2013, Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model, Toxicol Sci, 136, 581, 10.1093/toxsci/kft205

Gintant, 2016, Evolution of strategies to improve preclinical cardiac safety testing, Nat. Rev. Drug Discov, 15, 457, 10.1038/nrd.2015.34

Harris, 2013, Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays, Toxicol. Sci, 134, 412, 10.1093/toxsci/kft113

2016, The use of ratiometric fluorescence measurements of the voltage sensitive dye Di-4-ANEPPS to examine action potential characteristics and drug effects on human induced pluripotent stem cell-derived cardiomyocytes, Toxicol. Sci, 154, 320, 10.1093/toxsci/kfw171

Johannesen, 2014, Differentiating drug-induced multichannel block on the electrocardiogram: Randomized study of dofetilide, quinidine, ranolazine, and verapamil, Clin. Pharmacol. Ther, 96, 549, 10.1038/clpt.2014.155

Kitaguchi, 2016, CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia–effects of 7 reference compounds at 10 facilities, J. Pharmacol. Toxicol. Methods, 78, 93, 10.1016/j.vascn.2015.12.002

Kramer, 2013, MICE models: Superior to the HERG model in predicting Torsade de Pointes, Sci. Rep, 3, 2100., 10.1038/srep02100

Ma, 2011, High purity human-induced pluripotent stem cell-derived cardiomyocytes : Electrophysiological properties of action potentials and ionic currents, Am. J. Physiol. Heart Circ. Physiol, 301, H2006, 10.1152/ajpheart.00694.2011

Meiry, 2001, Evolution of action potential propagation and repolarization in cultured neonatal rat ventricular myocytes, J. Cardiovasc. Electrophysiol, 12, 1269, 10.1046/j.1540-8167.2001.01269.x

83

Nakamura, 2014, Assessment of testing methods for drug-induced repolarization delay and arrhythmias in an iPS cell-derived cardiomyocyte sheet: Multi-site validation study, J. Pharmacol. Sci, 124, 494, 10.1254/jphs.13248FP

Navarrete, 2013, Screening drug-induced arrhythmia events using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays, Circulation, 128, S3, 10.1161/CIRCULATIONAHA.112.000570

Qu, 2015, Proarrhythmia risk assessment in human induced pluripotent stem cell-derived cardiomyocytes using the maestro MEA platform, Toxicol. Sci, 286

Rast, 2016, Influence of field potential duration on spontaneous beating rate of human induced pluripotent stem cell-derived cardiomyocytes: Implications for data analysis and test system selection, J. Pharmacol. Toxicol. Methods, 82, 74, 10.1016/j.vascn.2016.08.002

Reppel, 2004, Microelectrode arrays: A new tool to measure embryonic heart activity, J. Electrocardiol, 37, 104, 10.1016/j.jelectrocard.2004.08.033

Sager, 2014, Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium, Am. Heart J, 167, 292, 10.1016/j.ahj.2013.11.004

Shah, 2005, Refining detection of drug-induced proarrhythmia: qT interval and TRIaD, Heart Rhythm, 2, 758, 10.1016/j.hrthm.2005.03.023

Thomas, 1972, A miniature microelectrode array to monitor the bioelectric activity of cultured cells, Exp. Cell Res, 74, 61, 10.1016/0014-4827(72)90481-8

Towart, 2009, Blockade of the IKspotassium channel: An overlooked cardiovascular liability in drug safety screening?, J. Pharmacol. Toxicol. Methods, 60, 1, 10.1016/j.vascn.2009.04.197

van den Heuvel, 2014, Lessons from the heart: Mirroring electrophysiological characteristics during cardiac development to in vitro differentiation of stem cell derived cardiomyocytes, J. Mol. Cell. Cardiol, 67, 12, 10.1016/j.yjmcc.2013.12.011